04
25
2021
Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president of pharmacology.
Dr. Chunlin Chen, the founder and CEO of Medicilon, welcomed the two and hoped that their participation will bring new innovation and development momentum to Medicilon, bringing a higher level of industry insight and strategic guidance.
04
19
2021
HG381 is new molecular entity developed by HitGen based on the DNA-encoded compound Library (DEL) technology and small molecule new drug research and development platform.As a leading R&D partner of HitGen, Shanghai Medicilon Inc. (Medicilon) provided preparation R&D services for HG381.
03
29
2021
Livzon Pharmaceutical Group Inc. (Livzon) obtained a "novel coronavirus recombinant protein vaccine" (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No. 2021L90001, 2021L90002, 2021L90003). V-01 is to prevent diseases caused by novel coronavirus infection.
02
10
2021
The preclinical pharmacology department of Medicilon has been deeply involved in this field for many years, and has provided a variety of stable and reliable animal models for different targets and pathways for the evaluation of inflammatory immune disease treatments in order for the successful clinical transformation.
01
01
2021
Medicilon embodies its motto of being "Innovation-driven, quality-focused" and keeps on maintaining and improving its technology and quality of services.Among all the positive things occurred in 2020, we chose what we thought was the Top 10 Greatest Achievements, highlighting a successful and productive year Medicilon had in 2020.
